Innovation in Protein Therapy for Atherosclerosis——Application of ApoA1
DOI:
https://doi.org/10.61173/ffsbvq26Keywords:
Atherosclerosis, metabolic diseases, lipid metabolism, cholesterol accumulation, ApoA1 modulationAbstract
Atherosclerosis is still the basic cause of metabolic diseases, namely the adnormal lipid metabolism and cholesterol accumulation. As more and more in-depth clinical investigations are being conducted, modulation the high-density lipoprotein (HDL) pathway, particularly the ApoA1, has been particularly attracted attention. Until now, to use these biotechnological functions properly and in management of individuals still poses a challenge. This essay will range from the introduction and discussion on the working and significance of both ApoA1 mimetics and genetically engineered ApoA1, focusing majorly on their functions which involve in enhancing cholesterol efflux and providing anti-inflammatory benefits. Consequently, they as a whole play a role in improving cardiovascular health. The results suggest that novel therapies could just be the epiphany for atherosclerosis cure or reversal. The study delineates the emphasis on protein-based treatments as a move for the future in the management of cardiovascular diseases, which serves as the architecture of subsequent research. However, as time goes on, matching treatment by patients’ genetic and environmental considerations stays to be a roadblock. Next research is set to target unsuitable combinations and those effective and possible in different groups for the development of such strategies.
References
recent years through the great advances in protein thera- [1] World Health Organization. Cardiovascular diseases (CVDs). py, protein engineering and combining these approaches Retrieved from https://www.who.int/news-room/fact-sheets/ together. The exploration into the methods of ApoA1 mi- detail/cardiovascular-diseases-(cvds). 2021. metics and their development via gene engineering serves [2] Rosenson, R. S., Brewer, H. B. Jr., Davidson, W. S., Fayad, to stress their important operations that are essential in Z. A., Fuster, V., Goldstein, J., ... & Tall, A. R. Cholesterol boosting cholesterol efflux and have anti-inflammatory efflux and atheroprotection: Advancing the concept of reverse qualities which are useful in amoeliorating and even re- cholesterol transport. Circulation, 2019, 125(15), 1905-1919. versing atherosclerosis. [3] Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, This study achievement is reflected in its capacity to link F., Borén, J., Catapano, A. L., ... & Nordestgaard, B. G. usual lipid medications and interesting techniques that are Triglyceride-rich lipoproteins and high-density lipoprotein centered on proteins. By knowing the functional mecha- cholesterol in patients at high risk of cardiovascular disease: nisms of ApoA1 and its genetically altered counterparts, evidence and guidance for management. European Heart Journal, it is assuring to know that this is paving the way to more 2010, 31(11), 1345-1361. therapeutic treatments than those currently in use for car- [4] Rader, D. J., & Hovingh, G. K. HDL and cardiovascular diovascular diseases. It can be said that this study is part disease. The Lancet, 2014, 384(9943), 618-625. of the efforts of cardiovascular health and place ApoA1 [5] Tardif, J. C., Grégoire, J., L’Allier, P. L., Anderson, T. line of mimetics and similar drugs on the list of innovative J., Bertrand, O., Reeves, F., ... & Lespérance, J. Effects of cardiovascular disease strategies. This study has led to a reconstituted high-density lipoprotein infusions on coronary better understanding of how these proteins function and atherosclerosis: a randomized controlled trial. JAMA, 2017, how the research can be a starting point for future studies, 297(15), 1675-1682. which may lead to substantial advancements in cardiovas- [6] Ansell, B. J., Navab, M., Hama, S., Kamranpour, N., cular medicine. Fonarow, G., Hough, G., ... & Lusis, A. J. Inflammatory/ But the survey has those, its complexity which is hard to antiinflammatory properties of high-density lipoprotein diagnose due to the multigeneration phenomena of ath- distinguish patients from control subjects better than higherosclerosis and individual variety toward the treatments. density lipoprotein cholesterol levels and are favorably affected This work tackled the task of evaluating the role of dif- by simvastatin treatment. Circulation, 2003, 108(22), 2751-6. ferent macronutrients in the gut microbiota, discussing [7] Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, the relative contribution of each to overall human health. T., & Wang, N. HDL, ABC transporters, and cholesterol Moreover, the research is not detailed about the genetic efflux: implications for the treatment of atherosclerosis. Cell and environmental impact to treatment effecting ApoA1 Metabolism, 2008, 7(5), 365-75. etohers.as this paper further explores the clinical appli- [8] Silva, R. A. G. D., Huang, R., Morris, J., Fang, J., Gracheva, E. O., Ren, G., ... & Maxfield, F. R. Structure of apolipoprotein
A-I in spherical high density lipoproteins of different sizes. antiinflammatory properties of high-density lipoprotein Proceedings of the National Academy of Sciences, 2008, distinguish patients from control subjects better than high- 105(34), 12176-81. density lipoprotein cholesterol levels and are favorably affected [9] Otocka-Kmiecik, A., Mikhailidis, D. P., Nicholls, S. by simvastatin treatment. Circulation. 2003. J., Davidson, M., Rysz, J., & Banach, M. Dysfunctional [11] Tardif, J. C., Gregoire, J., L’Allier, P. L., et al. Effects of HDL: a novel important diagnostic and therapeutic target in reconstituted high-density lipoprotein infusions on coronary cardiovascular disease? Progress in Lipid Research, 2012, 51(4), atherosclerosis: a randomized controlled trial. Journal of the 314-24. American Medical Association. 2007. [10] Ansell, B. J., Navab, M., Hama, S., et al. Inflammatory/
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
